News

From 1990-2021, global CKD-related deaths and DALYs attributable to physical inactivity increased, especially in low-SDI regions and among females.

Data suggest that etripamil may be more effective than vagal maneuvers and oral prophylaxis, minimizing emergency department visits.

Trial data reveal phentolamine ophthalmic solution's potential to treat night vision disturbances post-keratorefractive surgery, addressing a critical unmet need.

These data were the conclusion of a case series highlighting the experiences and responses of African American patients with alopecia areata who utilize JAK inhibitors.

Cutler told HCPLive it was surprising that a new survey on subcutaneous TEV- ‘749 revealed 50% and 45.5% of nurses and physicians, respectively, preferred intramuscular injections.

Findings suggest the benefit of MASLD-focused anti-inflammatory interventions for promoting brain health and preventing accelerated brain aging.

In this episode, hosts explore the findings of the Catalyst trial on hypercortisolism and its impact on type 2 diabetes.

New research links increased dietary selenium intake to reduced cardiovascular disease risk, highlighting its potential benefits for heart health.

This FDA approval makes pz-cel the first single application therapy to receive FDA approval for recessive dystrophic epidermolysis bullosa.

Norouzi discusses recent advancements in IgAN therapeutics and looks ahead to a potential first FDA-approved FSGS treatment.

These findings point to a need for evidence-based digital health information access to counter misinformation regarding androgenetic alopecia.

Findings suggest greater physical activity volume and intensity are linked to a reduced risk of all-cause and cardiovascular disease mortality in MASLD.

Phentolamine ophthalmic solution significantly enhances outcomes post-dilation, rapidly returning visual symptoms to baseline levels.

Lifitegrast shows rapid and sustained relief for dry eye disease, with high satisfaction among providers and patients, according to recent findings.

Younger age and recurrent disease significantly increase the risk of pterygium progression, highlighting critical factors for ophthalmologists.

A study reveals Johnson & Johnson’s TECNIS Odyssey IOL offers excellent vision for presbyopia, with minimal dysphotopsia bothersomeness reported by patients.

BRIMOCHOL PF offers lasting near vision improvement for presbyopia, demonstrating robust efficacy and safety in a landmark Phase 3 study.

Travoprost intracameral implant significantly reduces intraocular pressure and medication use in patients with glaucoma over three years.

A Phase 1/2 trial shows promising results for corneal edema, highlighting significant visual and quality of life improvements with an innovative cell therapy.

Long-term analysis confirms lifitegrast's safety for dry eye treatment, showing no new safety signals in nearly 800,000 patient treatment years.

Cyclosporine 0.09% significantly improves dry eye symptoms in patients inadequately treated with lower concentrations, enhancing quality of life.

Gene therapy could revolutionize retinal disease treatment, promising consistent dosing, fewer injections, and improved patient outcomes, as highlighted by expert Christina Y. Weng.

Using the American Heart Association’s Life’s Essential 8 model, researchers indicated that preventative action early in life can reduce chances of developing cardiovascular disease later.

Innovative drug delivery platform shows significant vision improvement and IOP reduction in glaucoma patients, promising a new treatment paradigm.

Jeffrey Levenson, MD, discusses the sustained reduction of ocular inflammation and pain post ocular surgery with clobetasol propionate ophthalmic suspension.

Katherine Talcott, MD, discuss the impact of intravitreal injections on intraocular pressure, emphasizing monitoring and patient safety in treatment.

Young shared with his real-world experiences with etranacogene dezaparvovec gene therapy.

Christina Y. Weng, MD, breaks down emerging gene therapy programs poised to change how retina specialists treat chronic eye disease.